LMNA PRIORITY (Leducq Foundation)

LMNA PRIORITY (Leducq Foundation) is dedicated to advancing research services in the critical area of cardio-laminopathy. Through the Cardio-LaminoPathy: fRom pathomechanIsms tO peRsonalIzed TherapY (PRIORITY) network, LMNA PRIORITY aims to deepen the understanding of LMNA-related dilated cardiomyopathy (LMNA-DCM), a severe inherited disease caused by mutations in the LMNA gene. This initiative seeks to unravel the complex cellular and molecular processes underlying the pathogenesis and disease progression, utilizing state-of-the-art technologies.

LMNA PRIORITY's core mission revolves around identifying clinical and genetic signs associated with LMNA-DCM, pinpointing factors influencing the severity and progression of the disease. By leveraging existing concepts and novel findings, LMNA PRIORITY is committed to developing mechanism-based therapies for LMNA-related DCM, potentially offering personalized therapeutic options for patients. The network includes internationally renowned experts from prestigious European and American institutions, ensuring a comprehensive and cutting-edge approach to research.

With a patient-centered focus, LMNA PRIORITY collaborates with the LMNA Cardiac Diseases Network to address the needs of those affected by LMNA-DCM. The ultimate goal is to translate research findings into effective treatments and improved patient outcomes. We invite the manager of LMNA PRIORITY (Leducq Foundation) to create a customized and exclusive company showcase and product listing on our platform to further highlight their vital work.